Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 20:10:1085010.
doi: 10.3389/fmed.2023.1085010. eCollection 2023.

Effectiveness and safety of Levofloxacin containing regimen in the treatment of Isoniazid mono-resistant pulmonary Tuberculosis: a systematic review

Leeberk Raja Inbaraj  1 , Hemant Deepak Shewade  2 , Jefferson Daniel  3 , Vignes Anand Srinivasalu  1 , Jabez Paul  4 , S Satish  2 , Richard Kirubakaran  5 , Chandrasekaran Padmapriyadarsini  1
Affiliations

Effectiveness and safety of Levofloxacin containing regimen in the treatment of Isoniazid mono-resistant pulmonary Tuberculosis: a systematic review

Leeberk Raja Inbaraj et al. Front Med (Lausanne). .

Abstract

Background: We aimed to determine the effectiveness and safety of the Levofloxacin-containing regimen that the World Health Organization is currently recommending for the treatment of Isoniazid mono-resistant pulmonary Tuberculosis.

Methods: Our eligible criteria for the studies to be included were; randomized controlled trials or cohort studies that focused on adults with Isoniazid mono-resistant tuberculosis (HrTB) and treated with a Levofloxacin-containing regimen along with first-line anti-tubercular drugs; they should have had a control group treated with first-line without Levofloxacin; should have reported treatment success rate, mortality, recurrence, progression to multidrug-resistant Tuberculosis. We performed the search in MEDLINE, EMBASE, Epistemonikos, Google Scholar, and Clinical trials registry. Two authors independently screened the titles/abstracts and full texts that were retained after the initial screening, and a third author resolved disagreements.

Results: Our search found 4,813 records after excluding duplicates. We excluded 4,768 records after screening the titles and abstracts, retaining 44 records. Subsequently, 36 articles were excluded after the full-text screening, and eight appeared to have partially fulfilled the inclusion criteria. We contacted the respective authors, and none responded positively. Hence, no articles were included in the meta-analysis.

Conclusion: We found no "quality" evidence currently on the effectiveness and safety of Levofloxacin in treating HrTB.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022290333, identifier: CRD42022290333.

Keywords: Isoniazid resistance; MDR-TB; fluoroquinolones; levofloxacin; resistant pulmonary Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization. Global Tuberculosis Report 2021. World Health Organization (2021). Available online at: https://apps.who.int/iris/handle/10665/346387 (accessed October 20, 2022).
    1. World Health Organization. Global Tuberculosis Report 2014. World Health Organization (2014). Available online at: http://apps.who.int/iris/handle/10665/137094 (accessed October 20, 2022).
    1. Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics. (2015) 136:e50–9. 10.1542/peds.2015-0172 - DOI - PMC - PubMed
    1. Ministry of Health Family Welfare Government of India Coming Together to End TB Altogether. (2022). Available online at: https://tbcindia.gov.in/WriteReadData/IndiaTBReport2022/TBAnnaulReport20... (accessed October 20, 2022).
    1. Jhun BW, Koh W-J. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis. (2020) 83:20. 10.4046/trd.2019.0065 - DOI - PMC - PubMed

Publication types

LinkOut - more resources